Literature DB >> 32389443

Routine Use of Magnetic Resonance Imaging for Early Detection of Prostate Cancer Is Not Justified by the Clinical Trial Evidence.

Andrew Vickers1, Sigrid V Carlsson2, Matthew Cooperberg3.   

Abstract

Guidelines now recommend multiparametric magnetic resonance imaging before prostate biopsy in the work-up for patients with elevated prostate specific-antigen. However, use of magnetic resonance imaging for early detection of prostate cancer is not justified by the clinical trial evidence.
Copyright © 2020 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Entities:  

Year:  2020        PMID： 32389443     DOI： 10.1016/j.eururo.2020.04.016

Source DB:  PubMed          Journal:  Eur Urol        ISSN： 0302-2838            Impact factor:   20.096


  9 in total

1.  Role of MRI for the detection of prostate cancer.

Authors:  Richard C Wu; Amir H Lebastchi; Boris A Hadaschik; Mark Emberton; Caroline Moore; Pilar Laguna; Jurgen J Fütterer; Arvin K George
Journal:  World J Urol       Date:  2021-01-04       Impact factor: 4.226

2.  Reducing Biopsies and Magnetic Resonance Imaging Scans During the Diagnostic Pathway of Prostate Cancer: Applying the Rotterdam Prostate Cancer Risk Calculator to the PRECISION Trial Data.

Authors:  Sebastiaan Remmers; Veeru Kasivisvanathan; Jan F M Verbeek; Caroline M Moore; Monique J Roobol
Journal:  Eur Urol Open Sci       Date:  2021-12-15

3.  The ReIMAGINE prostate cancer risk study protocol: A prospective cohort study in men with a suspicion of prostate cancer who are referred onto an MRI-based diagnostic pathway with donation of tissue, blood and urine for biomarker analyses.

Authors:  Teresa Marsden; Neil McCartan; Louise Brown; Manuel Rodriguez-Justo; Tom Syer; Giorgio Brembilla; Mieke Van Hemelrijck; Ton Coolen; Gerhardt Attard; Shonit Punwani; Caroline M Moore; Hashim U Ahmed; Mark Emberton
Journal:  PLoS One       Date:  2022-02-24       Impact factor: 3.240

Review 4.  Diagnostic Performance of a Magnetic Resonance Imaging-directed Targeted plus Regional Biopsy Approach in Prostate Cancer Diagnosis: A Systematic Review and Meta-analysis.

Authors:  Marinus J Hagens; Mar Fernandez Salamanca; Anwar R Padhani; Pim J van Leeuwen; Henk G van der Poel; Ivo G Schoots
Journal:  Eur Urol Open Sci       Date:  2022-05-02

5.  Individualised non-contrast MRI-based risk estimation and shared decision-making in men with a suspicion of prostate cancer: protocol for multicentre randomised controlled trial (multi-IMPROD V.2.0).

Authors:  Otto Ettala; Ivan Jambor; Ileana Montoya Perez; Marjo Seppänen; Antti Kaipia; Heikki Seikkula; Kari T Syvänen; Pekka Taimen; Janne Verho; Aida Steiner; Jani Saunavaara; Ekaterina Saukko; Eliisa Löyttyniemi; Daniel D Sjoberg; Andrew Vickers; Hannu Aronen; Peter Boström
Journal:  BMJ Open       Date:  2022-04-15       Impact factor: 3.006

6.  Assessing the impact of MRI based diagnostics on pre-treatment disease classification and prognostic model performance in men diagnosed with new prostate cancer from an unscreened population.

Authors:  Artitaya Lophatananon; Matthew H V Byrne; Tristan Barrett; Anne Warren; Kenneth Muir; Ibifuro Dokubo; Fanos Georgiades; Mostafa Sheba; Lisa Bibby; Vincent J Gnanapragasam
Journal:  BMC Cancer       Date:  2022-08-11       Impact factor: 4.638

7.  Predicting Grade group 2 or higher cancer at prostate biopsy by 4Kscore in blood and uCaP microRNA model in urine.

Authors:  Jacob Fredsøe; Martin Rasmussen; Amy L Tin; Andrew J Vickers; Michael Borre; Karina D Sørensen; Hans Lilja
Journal:  Sci Rep       Date:  2022-09-07       Impact factor: 4.996

8.  Disparities in magnetic resonance imaging of the prostate for traditionally underserved patients with prostate cancer.

Authors:  Timothy P Quinn; Martin G Sanda; David H Howard; Dattatraya Patil; Christopher P Filson
Journal:  Cancer       Date:  2021-06-17       Impact factor: 6.921

9.  Effects of Magnetic Resonance Imaging Targeting on Overdiagnosis and Overtreatment of Prostate Cancer.

Authors:  Andrew J Vickers
Journal:  Eur Urol       Date:  2021-07-20       Impact factor: 24.267
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.